You are here

Phase 3 Results for Kogenate FS Presented at Hemophilia Meeting

Bayer Healthcare released preliminary data to the press on July 12.

A total of 84 subjects aged 12 to 50 years were randomly assigned to receive either prophylaxis with Kogenate FS (25 IU/kg three times per week) or on-demand treatment, with a planned follow-up period of 3 years.

After a median follow-up period of 1.7 years, significantly fewer bleeding events occurred per year with prophylaxis versus on-demand treatment (median, 0.0 vs. 27.9, respectively; P

Kogenate FS, antihemophilic factor (recombinant), is a recombinant factor V3 treatment indicated for the control and prevention of bleeding episodes and perioperative management in adults and children with hemophilia A. Kogenate FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no pre-existing joint damage.

Bayer submitted an application to the FDA requesting an adult prophylaxis indication for Kogenate FS on June 21.

For more information, read the news article in the Sacramento Bee.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year